Status:
COMPLETED
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
Lead Sponsor:
Allergan
Conditions:
Inflammation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Eligibility Criteria
Inclusion
- Patients scheduled to undergo phakic IOL implantation
Exclusion
- History of intraocular surgery in the operative eye
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00791323
Start Date
November 1 2008
End Date
August 1 2009
Last Update
September 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston, Texas, United States